SFS
PCVX icon

Sowell Financial Services’s Vaxcyte PCVX Stock Holding History

Sowell Financial Services’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$3K – 2669
2020
Q2 		$3K Buy
+100
New +$3.22K ﹤0.01% 2068

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sowell Financial Services's PCVX Position: Q3 2020 in Review

Sowell Financial Services sold out of Vaxcyte (PCVX) in Q3 2020, closing a stake of 100 shares — an estimated $3K sold.

Sowell Financial Services first reported a position in PCVX in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 60 funds tracked by Wall St. Rank hold PCVX as of Q3 2020.

  • Sowell Financial Services reported no remaining Vaxcyte position as of Q3 2020 after selling out during the quarter.
  • Sowell Financial Services sold 100 Vaxcyte shares in Q3 2020, an estimated $3K.
  • Sowell Financial Services first reported a position in Vaxcyte in Q2 2020 and held it in 1 quarter.
  • Sowell Financial Services's Vaxcyte position peaked at $3K in Q2 2020.
  • 60 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2020.

Based on Sowell Financial Services's 13F filing for Q3 2020, filed 12 Nov 2020.